| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
Accelerated Approval Paths: What they do Mean and What they Should Not Mean?
|
Calvo, G.
|
|
2016
|
|
10S |
p. e1-
1 p.
|
artikel
|
| 2 |
Adherence to Antiretroviral Therapy: Experience of Pharmaceutical Services of Maputo Central Hospital
|
Cumaquela, F.
|
|
2016
|
|
10S |
p. e26-
1 p.
|
artikel
|
| 3 |
Adherence To Pharmacological Treatment Of Chronic Non-Malignant Pain In Individuals Aged 65 and Older
|
Markotic, F.
|
|
2016
|
|
10S |
p. e11-
1 p.
|
artikel
|
| 4 |
Allele Frequency Distribution of CYP2C19 Genotypes Associated with Clopidogrel Resistance in Russian Population
|
Barysheva, V.
|
|
2016
|
|
10S |
p. e25-e26
nvt p.
|
artikel
|
| 5 |
A Model For Managed Introduction Of New Medicines In Sweden
|
Böttiger, Y.
|
|
2016
|
|
10S |
p. e13-e14
nvt p.
|
artikel
|
| 6 |
Antibiotic Use In Hospital Setting: Have Pharmacists An Active Role?
|
Roque, F.
|
|
2016
|
|
10S |
p. e29-
1 p.
|
artikel
|
| 7 |
Anticoagulation For The Prevention of Stroke In Non-Vavular Af In General Practice: Room For Improvement
|
Ioannou, A.
|
|
2016
|
|
10S |
p. e29-e30
nvt p.
|
artikel
|
| 8 |
Application of Physiologically Based Pharmacokinetic Modeling In Predicting Drug-Drug Interactions For Sarpogrelate Hydrochloride In Humans
|
Min, J.S.
|
|
2016
|
|
10S |
p. e32-
1 p.
|
artikel
|
| 9 |
Are we Scared of Clinical Trials if not Sufficiently Informed and Educated?
|
Burnazovic-Ristic, L.
|
|
2016
|
|
10S |
p. e4-e5
nvt p.
|
artikel
|
| 10 |
Attitudes to Performing Clinical Trials
|
Potocnjak, I.
|
|
2016
|
|
10S |
p. e5-
1 p.
|
artikel
|
| 11 |
Availability and Affordability of Cardiovascular Medicines In Armenia
|
Sevikyan, A.L.
|
|
2016
|
|
10S |
p. e27-
1 p.
|
artikel
|
| 12 |
Availability of Information on use of Medicines in Children in Reference Books
|
Melikyan, M.V.
|
|
2016
|
|
10S |
p. e21-
1 p.
|
artikel
|
| 13 |
Can Vascular Calcification be Associated with Warfarin Treatment?
|
Siltari, A.
|
|
2016
|
|
10S |
p. e25-
1 p.
|
artikel
|
| 14 |
Can You Blindly Trust Decisions Made By Stringent Drug Regulatory Agencies?
|
Ahmad, S.R.
|
|
2016
|
|
10S |
p. e30-
1 p.
|
artikel
|
| 15 |
Clinical Drug-Drug Interaction Studies: Methods, Pitfalls, and Interpretation
|
Backman, J.T.
|
|
2016
|
|
10S |
p. e1-e2
nvt p.
|
artikel
|
| 16 |
Clinically Guided Warfarin Dose Versus Genotyping In Early Achievement Of Stable Anticoagulant Effect Of Warfarin
|
Makar-Ausperger, K.
|
|
2016
|
|
10S |
p. e10-
1 p.
|
artikel
|
| 17 |
Clinical Pharmacology As A Key Principle Of Precision Medicine In Korea
|
Shin, J.G.
|
|
2016
|
|
10S |
p. e7-
1 p.
|
artikel
|
| 18 |
Clinical Safety and Efficacy Issues Ariding in Relation to Alternative Formulations of nti Drugs Relevant to National Policy Development and Reimbursement Decisions – Focus on Calcineurin Inhibitors (cni)
|
Undre, N.
|
|
2016
|
|
10S |
p. e15-
1 p.
|
artikel
|
| 19 |
Comparison Of Sorafenib Cost-Effectiveness And Budget Impact When Used For Advanced Hepatocellular Carcinoma In Two Neighbouring Balkan Countries
|
Jankovic, S.M.
|
|
2016
|
|
10S |
p. e16-e17
nvt p.
|
artikel
|
| 20 |
Cost Utility Analysis Of Selected Medical Equipment And Procedures In Croatia
|
Korolija Marinic, D.
|
|
2016
|
|
10S |
p. e15-
1 p.
|
artikel
|
| 21 |
Current Challenges and Hurdles in New Drug Development
|
Vukicevic, S.
|
|
2016
|
|
10S |
p. e3-
1 p.
|
artikel
|
| 22 |
Current Situation And Future Directions For Health Technology Assessment In Europe
|
Meyer, F.
|
|
2016
|
|
10S |
p. e14-e15
nvt p.
|
artikel
|
| 23 |
Decentralized Decision Making On Drug Reimbursement In A Middle-Income Country: Case Of Bosnia And Herzegovina
|
Mahmic-Kaknjo, M.
|
|
2016
|
|
10S |
p. e17-
1 p.
|
artikel
|
| 24 |
Direct Medical Costs Of Treating Colorectal Cancer Patients With Different Chemotherapy Protocols Regarding Stage And Outcome Of The Disease
|
Kovacevic, A.
|
|
2016
|
|
10S |
p. e17-
1 p.
|
artikel
|
| 25 |
Drug-Drug Interaction of Paroxetine and Atomoxetine in Different CYP2D6 Genotypes
|
Kim, Y.H.
|
|
2016
|
|
10S |
p. e23-
1 p.
|
artikel
|
| 26 |
Effectiveness Assessment When Pharmacokinetics Makes A Difference, Macrolides And Azalide Example
|
Francetic, I.
|
|
2016
|
|
10S |
p. e8-e9
nvt p.
|
artikel
|
| 27 |
Effect of Ondansetron On The Thermal Antinociceptive Effects of Procaine In The Rat Paw
|
Hanedan, B.
|
|
2016
|
|
10S |
p. e31-e32
nvt p.
|
artikel
|
| 28 |
Effects of ABCB1 Genetic Polymorphism on the Oral Absorption of Losartan
|
Byeon, J.Y.
|
|
2016
|
|
10S |
p. e22-
1 p.
|
artikel
|
| 29 |
Effects of Celastrol on Bv-2 Microglial Cells Exposed to in Vitro Hypoxia
|
Rački, V.
|
|
2016
|
|
10S |
p. e21-
1 p.
|
artikel
|
| 30 |
Effects of Genetic Polymorphism of Cyp2c19 on the Pharmacokinetics of Zolpidem
|
Byeon, J.Y.
|
|
2016
|
|
10S |
p. e22-e23
nvt p.
|
artikel
|
| 31 |
Efficacy of Antidepressants: Issues Related to Bias in Clinical Trials
|
Spina, E.
|
|
2016
|
|
10S |
p. e2-
1 p.
|
artikel
|
| 32 |
Evaluation of Drugs in the Pediatric Population
|
Mimica Matanovic, S.
|
|
2016
|
|
10S |
p. e2-
1 p.
|
artikel
|
| 33 |
Evaluation Of Medicines For Reimbursement By The National Social Insurance Institutions In Austria
|
Griesbacher, T.
|
|
2016
|
|
10S |
p. e14-
1 p.
|
artikel
|
| 34 |
Excellence in Clinical Research: Clinical Trial Design
|
Simon, T.
|
|
2016
|
|
10S |
p. e19-
1 p.
|
artikel
|
| 35 |
Experience from Development of Once-Weekly Glucagon-Like Peptide-1 Receptor Agonist (GLP-1 RA) Dulaglutide for Treatment of Type 2 Diabetes Mellitus
|
Milicevic, Z.
|
|
2016
|
|
10S |
p. e1-
1 p.
|
artikel
|
| 36 |
Following Guidelines and Prescribing Biological Medicine In A Situation of Reduced Budget
|
Zekić, T
|
|
2016
|
|
10S |
p. e27-
1 p.
|
artikel
|
| 37 |
Food And Drug Interactions
|
Bago, M.
|
|
2016
|
|
10S |
p. e10-
1 p.
|
artikel
|
| 38 |
Frequency of Potentially Dangerous Drug Combination Prescription in Elderly Patients with Cardiovascular Diseases
|
Bordovsky, S.
|
|
2016
|
|
10S |
p. e22-
1 p.
|
artikel
|
| 39 |
Genetic and Non-Genetic Factors Affecting The Response To Clopidogrel Therapy
|
Mugosa, S.
|
|
2016
|
|
10S |
p. e11-
1 p.
|
artikel
|
| 40 |
Health Technology Assessment (Hta) In Croatia: National And International View
|
Huic, M.
|
|
2016
|
|
10S |
p. e16-
1 p.
|
artikel
|
| 41 |
How To Assess The Value Of The Drug? An Overview On Producing Economic Evidence In The R&D Process
|
Kaló, Z.
|
|
2016
|
|
10S |
p. e14-
1 p.
|
artikel
|
| 42 |
How to Promote Clinical Research in Cee?
|
Spaventi, R.
|
|
2016
|
|
10S |
p. e3-
1 p.
|
artikel
|
| 43 |
Implementation of Pharmacoeconomics to Support Pharmaceutical R&D Decisions Workshop
|
Kaló, Z.
|
|
2016
|
|
10S |
p. e19-
1 p.
|
artikel
|
| 44 |
Inconsistency in Preclinical and Clinical Trials Exploring The Role of Hormone Replacement Therapy in Alzheimer’s Disease
|
Osmanovic-Barilar, J.
|
|
2016
|
|
10S |
p. e4-
1 p.
|
artikel
|
| 45 |
Integrating Pharmacovigilance and Pharmacogenomics: Croatian Experience
|
Bozina, N.
|
|
2016
|
|
10S |
p. e23-
1 p.
|
artikel
|
| 46 |
Managing Increasing Expenses For Oncology Treatment In Lower Income Countries In Europe
|
Bolanča, Slobodanka
|
|
2016
|
|
10S |
p. e15-e16
nvt p.
|
artikel
|
| 47 |
Medicinal Product Regulation: Portugal’s Framework
|
Herdeiro, M.T.
|
|
2016
|
|
10S |
p. e3-e4
nvt p.
|
artikel
|
| 48 |
Medicines for Pain and Palliative Care in Armenia
|
Kazaryan, I.A.
|
|
2016
|
|
10S |
p. e21-e22
nvt p.
|
artikel
|
| 49 |
Neuroprotective And Memory-Enhancing Effects of The Water Extract From Pericarp of Mangosteen Fruit
|
Cho, J.
|
|
2016
|
|
10S |
p. e31-
1 p.
|
artikel
|
| 50 |
New drugs for bad bugs: what’s new and what’s in the pipeline?
|
Turk, V. Erdeljic
|
|
2016
|
|
10S |
p. e9-
1 p.
|
artikel
|
| 51 |
New Methods and Designs of Clinical Trials
|
Pontes, C.
|
|
2016
|
|
10S |
p. e2-e3
nvt p.
|
artikel
|
| 52 |
Osteogrow Development: Bmp6 Bone Device For Enhancing Bone Healing
|
Grgurevic, L.
|
|
2016
|
|
10S |
p. e9-e10
nvt p.
|
artikel
|
| 53 |
Outlook For Biosimilar Molecules Entering Croatian Pharmaceutical Market In The Period From 2016 To 2020
|
Likic, R.
|
|
2016
|
|
10S |
p. e16-
1 p.
|
artikel
|
| 54 |
Outpatient Use of Antidepressants And The Incidence of Suicide In Montenegro 2000-2015: Are We Going In Optimistic Direction?
|
Duborija-Kovacevic, N.
|
|
2016
|
|
10S |
p. e28-e29
nvt p.
|
artikel
|
| 55 |
Patient with Multiple Drugs Intolerance: Oral Drug Provocation Test
|
Havidic, A.
|
|
2016
|
|
10S |
p. e23-e24
nvt p.
|
artikel
|
| 56 |
Personalised Medicine Approaches For Identifying Effective Therapies
|
Singer, D.R.J.
|
|
2016
|
|
10S |
p. e7-
1 p.
|
artikel
|
| 57 |
Pharmaceutical Pricing: How Much for The Risk Of Non-Cure?
|
Mance, D.
|
|
2016
|
|
10S |
p. e17-e18
nvt p.
|
artikel
|
| 58 |
Pharmacoeconomic Analysis of Antithrombotic Treatment In Coronary Artery Disease (Cad) Patients With Clopidogrel Hypersensitivity After Percutaneous Coronary Intervention (Pci)
|
Cegec, I.
|
|
2016
|
|
10S |
p. e28-
1 p.
|
artikel
|
| 59 |
Pharmacoeconomics: How It Can Be Applied To Support Decisions In Health Care?
|
Vitezic, D.
|
|
2016
|
|
10S |
p. e13-
1 p.
|
artikel
|
| 60 |
Pregnancy Exposure to Drugs: Role of Clinical Pharmacologist
|
Radacic Aumiler, M.
|
|
2016
|
|
10S |
p. e21-
1 p.
|
artikel
|
| 61 |
Rapid Health Technology Assessment Of New Medicines: Lessons From 15 Years Experience In Scotland
|
Paterson, K.R.
|
|
2016
|
|
10S |
p. e13-
1 p.
|
artikel
|
| 62 |
Regulation Of Orphan Medicinal Products In Europe: History Trends And Challenges
|
Sepodes, B.
|
|
2016
|
|
10S |
p. e7-e8
nvt p.
|
artikel
|
| 63 |
Safe Introduction of New Medicines Into Clinical Practice
|
Maxwell, S.
|
|
2016
|
|
10S |
p. e8-
1 p.
|
artikel
|
| 64 |
Sodium Selenate Restores Potassium Currents of Diabetic Cardiomyopathy: Rat Model Study
|
Yanardag, S.B.
|
|
2016
|
|
10S |
p. e30-e31
nvt p.
|
artikel
|
| 65 |
Standardization of In Vivo Drug Assessment Protocol For Testing Anti-Diabetic Plants: Effect And Possible Mechanism of Action of Fabaceae Beans
|
Senbel, A.
|
|
2016
|
|
10S |
p. e32-
1 p.
|
artikel
|
| 66 |
Table of Contents
|
|
|
2016
|
|
10S |
p. A3-
1 p.
|
artikel
|
| 67 |
Testing for Hypersensitivity to Nonsteroidal Anti-Inflammatory Drugs (NSAIDS) At the University Hospital Zagreb
|
Kraljickovic, I.
|
|
2016
|
|
10S |
p. e25-
1 p.
|
artikel
|
| 68 |
The Analysis Of Lipid Modifying Agents Usage In Croatia During The Fifteen-Year Period
|
Kucan, M.
|
|
2016
|
|
10S |
p. e10-
1 p.
|
artikel
|
| 69 |
The Effects of SENS-111, A New H4R Antagonist, On Vertigo Induced by Caloric Test in Healthy Volunteers (HV) is Related to Plasma Concentrations
|
Attali, P.
|
|
2016
|
|
10S |
p. e4-
1 p.
|
artikel
|
| 70 |
The Modification of Anti-Inflammatory Properties of the Combined use of Nsaids and Glucosamine in Topical Dosage Form for Degenerative and Inflammatory Joint Diseases Treatment
|
Davishnia, N.V.
|
|
2016
|
|
10S |
p. e24-
1 p.
|
artikel
|
| 71 |
The Need For Medical Information In Relation To Diabetes Self-Management Among Emirati Women In United Arab Emirates
|
Abuelmagd, W.
|
|
2016
|
|
10S |
p. e29-
1 p.
|
artikel
|
| 72 |
The Role Of Cyp2d6, Cyp3a4/5, And Abcb1 Polymorphisms In Patients Using Long-Acting Injectable Risperidone
|
Ganoci, L.
|
|
2016
|
|
10S |
p. e10-e11
nvt p.
|
artikel
|
| 73 |
The Role Of Pharmacogenetics In Individualized Treatment Choices
|
Bozina, N.
|
|
2016
|
|
10S |
p. e7-
1 p.
|
artikel
|
| 74 |
The Role of Pharmacogenetic Testing in the Evaluation of Drug-Induced Liver Injury
|
Stanić Benić, M.
|
|
2016
|
|
10S |
p. e24-e25
nvt p.
|
artikel
|
| 75 |
The Role of the National Competent Authority (NCA) In the Assessment of Medicinal Products in the National Procedure
|
Tomic, S.
|
|
2016
|
|
10S |
p. e2-
1 p.
|
artikel
|
| 76 |
The Use of Drugs for The Elderly With Community-Acquired Pneumonia
|
Tilekeeva, U
|
|
2016
|
|
10S |
p. e27-e28
nvt p.
|
artikel
|
| 77 |
Trend of Biosimilars Prescribing In A Croatian Teaching Hospital
|
Stanic Benic, M.
|
|
2016
|
|
10S |
p. e28-
1 p.
|
artikel
|
| 78 |
Use of Health Technology Assessment Agencies' Reports As Evidence For Making Decisions On Drug Reimbursement In Decentralized Decision-Making Environment
|
Mahmic-Kaknjo, M.
|
|
2016
|
|
10S |
p. e30-
1 p.
|
artikel
|
| 79 |
Vascular Consequences Of Interruption Of Tnf-Inhibitor Therapy In Patients With Rheumatoid Arthritis
|
Rongen, G.A.
|
|
2016
|
|
10S |
p. e8-
1 p.
|
artikel
|
| 80 |
Why Abc/Ved Analysis In Oncology? The Experience Of A Major Russian Oncology Center
|
Pavlysh, A.V.
|
|
2016
|
|
10S |
p. e18-
1 p.
|
artikel
|
| 81 |
Why Reporting The Iodinated Contrast Media Used During Radiological Procedures Should Be Standard Practice: A Case Report
|
Juricic Nahal, D.
|
|
2016
|
|
10S |
p. e31-
1 p.
|
artikel
|
Tijdschrift beschrijving